Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review.

Br J Haematol · 2022 · PMC9796722 · PMID 35796524

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an observed trendno p-value reported

In the STaMINA study, there was no benefit with regards to PFS or OS with the use of four cycles of consolidation RVD post‐ASCT, except for an observed trend for PFS benefit in the high‐risk population. 44 In all, 55% of these patients received RVD induction.

also in 504 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.